Cargando…
A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model
The overexpression of chondroitin sulfate proteoglycan 4 (CSPG4) is associated with several tumor types, including malignant melanoma, squamous cell carcinoma, triple-negative breast carcinoma, oligodendrocytomas or gliomas. Due to its restricted distribution in normal tissues, CSPG4 has been consid...
Autores principales: | Uranowska, Karolina, Samadaei, Mahzeiar, Kalic, Tanja, Pinter, Matthias, Breiteneder, Heimo, Hafner, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357264/ https://www.ncbi.nlm.nih.gov/pubmed/34318902 http://dx.doi.org/10.3892/ijo.2021.5250 |
Ejemplares similares
-
Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021) -
Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma
por: Grossauer, Anna, et al.
Publicado: (2023) -
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia
por: PUCCIARELLI, DANIELA, et al.
Publicado: (2015) -
Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma
por: Samadaei, Mahzeiar, et al.
Publicado: (2022) -
Newly defined allergens in the WHO/IUIS Allergen Nomenclature Database during 01/2019‐03/2021
por: Sudharson, Srinidhi, et al.
Publicado: (2021)